Trenkwalder, Claudia

[["dc.bibliographiccitation.journal","SLEEP"],["dc.bibliographiccitation.volume","30"],["dc.contributor.author","Happe, Svenja"],["dc.contributor.author","Stiasny-Kolster, Karin"],["dc.contributor.author","Peglau, Ines"],["dc.contributor.author","Mayer, G."],["dc.contributor.author","Giani, Guido"],["dc.contributor.author","Geraedts, Max"],["dc.contributor.author","Trenkwalder, Claudia"],["dc.contributor.author","Dodel, R."],["dc.date.accessioned","2018-11-07T11:07:35Z"],["dc.date.available","2018-11-07T11:07:35Z"],["dc.date.issued","2007"],["dc.format.extent","A281"],["dc.identifier.isi","000246224900820"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/52601"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Academy Sleep Medicine"],["dc.publisher.place","Westchester"],["dc.relation.conference","21st Annual Meeting of the Association-Professional-Sleep-Societies"],["dc.relation.eventlocation","Minneapolis, MN"],["dc.relation.issn","0161-8105"],["dc.title","Direct and indirect costs of restless legs syndrome (RLS)"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","946"],["dc.bibliographiccitation.issue","8"],["dc.bibliographiccitation.journal","Nature Genetics"],["dc.bibliographiccitation.lastpage","948"],["dc.bibliographiccitation.volume","40"],["dc.contributor.author","Schormair, Barbara"],["dc.contributor.author","Kemlink, David"],["dc.contributor.author","Roeske, Darina"],["dc.contributor.author","Eckstein, Gertrud"],["dc.contributor.author","Xiong, Lan"],["dc.contributor.author","Lichtner, Peter"],["dc.contributor.author","Ripke, Stephan"],["dc.contributor.author","Trenkwalder, Claudia"],["dc.contributor.author","Zimprich, Alexander"],["dc.contributor.author","Stiasny-Kolster, Karin"],["dc.contributor.author","Oertel, Wolfgang"],["dc.contributor.author","Bachmann, Cornelius G."],["dc.contributor.author","Paulus, Walter J."],["dc.contributor.author","Hoegl, Birgit"],["dc.contributor.author","Frauscher, Birgit"],["dc.contributor.author","Gschliesser, Viola"],["dc.contributor.author","Poewe, Werner"],["dc.contributor.author","Peglau, Ines"],["dc.contributor.author","Vodicka, Pavel"],["dc.contributor.author","Vavrova, Jana"],["dc.contributor.author","Sonka, Karel"],["dc.contributor.author","Nevsimalova, Sona"],["dc.contributor.author","Montplaisir, Jacques"],["dc.contributor.author","Turecki, Gustavo"],["dc.contributor.author","Rouleau, Guy A."],["dc.contributor.author","Gieger, Christian"],["dc.contributor.author","Illig, Thomas"],["dc.contributor.author","Wichmann, H-Erich"],["dc.contributor.author","Holsboer, Florian"],["dc.contributor.author","Mueller-Myhsok, Bertram"],["dc.contributor.author","Meitinger, Thomas"],["dc.contributor.author","Winkelmann, Juliane"],["dc.date.accessioned","2018-11-07T11:12:40Z"],["dc.date.available","2018-11-07T11:12:40Z"],["dc.date.issued","2008"],["dc.description.abstract","We identified association of restless legs syndrome (RLS) with PTPRD at 9p23-24 in 2,458 affected individuals and 4,749 controls from Germany, Austria, Czechia and Canada. Two independent SNPs in the 5' UTR of splice variants expressed predominantly in the central nervous system showed highly significant P values (rs4626664, P(nominal/lambda corrected) = 5.91 x 10(-10), odds ratio (OR) = 1.44; rs1975197, P(nominal/lambda corrected) = 5.81 x 10(-9), OR 1.31). This work identifies PTPRD as the fourth genome-wide significant locus for RLS."],["dc.identifier.doi","10.1038/ng.190"],["dc.identifier.isi","000258026900008"],["dc.identifier.pmid","18660810"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/53717"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Nature Publishing Group"],["dc.relation.issn","1061-4036"],["dc.title","PTPRD (protein tyrosine phosphatase receptor type delta) is associated with restless legs syndrome"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","S495"],["dc.bibliographiccitation.journal","Movement Disorders"],["dc.bibliographiccitation.lastpage","S504"],["dc.bibliographiccitation.volume","22"],["dc.contributor.author","Trenkwalder, Claudia"],["dc.contributor.author","Kohnen, Ralf"],["dc.contributor.author","Allen, Richard P."],["dc.contributor.author","Benes, Heike"],["dc.contributor.author","Ferini-Strambi, Luigi"],["dc.contributor.author","Garcia-Borreguero, Diego"],["dc.contributor.author","Hadjigeorgiou, Georgios M."],["dc.contributor.author","Happe, Svenja"],["dc.contributor.author","Hoegl, Birgit"],["dc.contributor.author","Hornyak, Magdolna"],["dc.contributor.author","Klein, Christine"],["dc.contributor.author","Nass, Alexander"],["dc.contributor.author","Montagna, Pasquale"],["dc.contributor.author","Oertel, Wolfgang Hermann"],["dc.contributor.author","O'Keeffe, Shaun"],["dc.contributor.author","Paulus, Walter J."],["dc.contributor.author","Poewe, Werner"],["dc.contributor.author","Provini, Federica"],["dc.contributor.author","Pramstaller, Peter P."],["dc.contributor.author","Sieminski, Mariusz"],["dc.contributor.author","Sonka, Karel"],["dc.contributor.author","Stiasny-Kolster, Karin"],["dc.contributor.author","de Weerd, A. L."],["dc.contributor.author","Wetter, Thomas C."],["dc.contributor.author","Winkelmann, Juliane"],["dc.contributor.author","Zucconi, Marco"],["dc.date.accessioned","2018-11-07T11:07:07Z"],["dc.date.available","2018-11-07T11:07:07Z"],["dc.date.issued","2007"],["dc.description.abstract","The European Restless Leas Syndrome (RLS) Study Group (EURLSSG) is an association of European RLS experts who are actively involved in RLS research. A major aim of the Study Group is the development and continuous improvement of standards for diagnosis and treatment of RLS. Several members developed study designs and evaluation methods in investigator-initiated trials early in the 1990s, and all members have since contributed to many pivotal and nonpivotal drug trials for the treatment of RLS. The recommendations on clinical investigations of pharmacological treatment of RLS patients summarize the group's expertise and knowledge acquired through clinical trials. The recommendations primarily address how to plan and conduct confirmatory, randomized clinical studies in patients with idiopathic RLS. Advice is presented for the diagnosis of RLS and clinical and polysomnographic inclusion and exclusion criteria. Primary and secondary endpoints for an evaluation of efficacy are based on a critical description of validated methods for both short- and long-term trials, also in special populations (children, pregnant women, elderly patients). The recommendations include the assessment of augmentation. Finally, general issues including the evaluation of safety and tolerability, as well as specific neurological and cardiovascular risks and sleep attacks/daytime somnolence, are discussed. The aim of these recommendations is to support research groups or pharmaceutical companies in the design of optimized study protocols. (C) 2007 Movement Disorder Society."],["dc.identifier.doi","10.1002/mds.21538"],["dc.identifier.isi","000251605200015"],["dc.identifier.pmid","17530666"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/52479"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-blackwell"],["dc.publisher.place","Hoboken"],["dc.relation.conference","Scientific Symposium and Augmentation Workshop on Restless Leg Syndrome"],["dc.relation.eventlocation","Max Planck Inst Phys Complex Syst, Munich, GERMANY"],["dc.relation.issn","1531-8257"],["dc.relation.issn","0885-3185"],["dc.title","Clinical trials in restless legs syndrome - Recommendations of the European RLS study group (EURLSSG)"],["dc.type","conference_paper"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","SLEEP"],["dc.bibliographiccitation.volume","29"],["dc.contributor.author","Trenkwalder, Claudia"],["dc.contributor.author","Stiasny-Kolster, Karin"],["dc.contributor.author","Kupsch, Andreas"],["dc.contributor.author","Oertel, Wolfgang Hermann"],["dc.contributor.author","Koester, J."],["dc.contributor.author","Reess, Juergen"],["dc.date.accessioned","2018-11-07T10:42:33Z"],["dc.date.available","2018-11-07T10:42:33Z"],["dc.date.issued","2006"],["dc.format.extent","A285"],["dc.identifier.isi","000237916701214"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/46824"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Academy Sleep Medicine"],["dc.publisher.place","Westchester"],["dc.relation.conference","20th Annual Meeting of the Associated-Professional-Sleep-Societies"],["dc.relation.eventlocation","Salt Lake City, UT"],["dc.relation.issn","0161-8105"],["dc.title","Rebound of sleep disturbance after rapid discontinuation of pramipexole in patients with restless legs syndrome"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","186"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Sleep Medicine"],["dc.bibliographiccitation.lastpage","189"],["dc.bibliographiccitation.volume","16"],["dc.contributor.author","Stiasny-Kolster, Karin"],["dc.contributor.author","Sixel-Doering, Friederike"],["dc.contributor.author","Trenkwalder, Claudia"],["dc.contributor.author","Heinzel-Gutenbrunner, Monika"],["dc.contributor.author","Seppi, Klaus"],["dc.contributor.author","Poewe, Werner"],["dc.contributor.author","Hoegl, Birgit"],["dc.contributor.author","Frauscher, Birgit"],["dc.date.accessioned","2018-11-07T10:03:50Z"],["dc.date.available","2018-11-07T10:03:50Z"],["dc.date.issued","2015"],["dc.description.abstract","Objective: We aimed to validate the rapid eye movement (REM) sleep behavior disorder (RBD) screening questionnaire (RBDSQ) in 2 independent samples of patients with Parkinson's disease (PD) using different settings when performing the investigations. Methods: The RBDSQ was administered to two independent samples of 52 and 75 consecutive PD patients investigated with video-polysomnography (vPSG). Results: In sample A, the RBDSQ identified 46/52 (88.5%) patients correctly. In sample B, 50/75 (66.7%) patients were identified correctly. Considering a cut-off score of >= 5 as a positive test result, sample A showed a sensitivity of 0.90 and a specificity of 0.87, sample B showed a sensitivity of 0.68 and a specificity of 0.63. Main differences between both groups were that patients of sample A underwent a sleep history including RBD assessment prior to administration of the RBDSQ, whereas in sample B the RBDSQ was administered during routine work-up. Conclusions: The diagnostic value of the RBDSQ strongly depends on the clinical setting and may be influenced by the individual's awareness on RBD. This finding is a critical issue which deserves clarification before use of this and other questionnaires can be recommended in epidemiological studies. (C) 2014 Elsevier B.V. All rights reserved."],["dc.identifier.doi","10.1016/j.sleep.2014.08.014"],["dc.identifier.isi","000348291900030"],["dc.identifier.pmid","25534709"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/38563"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Science Bv"],["dc.relation.issn","1878-5506"],["dc.relation.issn","1389-9457"],["dc.title","Diagnostic value of the REM sleep behavior disorder screening questionnaire in Parkinson's disease"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1404"],["dc.bibliographiccitation.issue","9"],["dc.bibliographiccitation.journal","Movement Disorders"],["dc.bibliographiccitation.lastpage","1410"],["dc.bibliographiccitation.volume","21"],["dc.contributor.author","Trenkwalder, Claudia"],["dc.contributor.author","Stiasny-Kolster, Karin"],["dc.contributor.author","Kupsch, Andreas"],["dc.contributor.author","Oertel, Wolfgang Hermann"],["dc.contributor.author","Koester, Juergen"],["dc.contributor.author","Reess, Juergen"],["dc.date.accessioned","2018-11-07T09:22:16Z"],["dc.date.available","2018-11-07T09:22:16Z"],["dc.date.issued","2006"],["dc.description.abstract","Although dopamine agonists are becoming first-line therapy for restless legs syndrome (RLS), few reports describe treatment periods exceeding 12 weeks. Here, 150 RLS Patients who had responded to pramipexole during a 6-month run-m period (mean dose, 0.50 mg) were randomly assigned to receive placebo or continue receiving pramipexole at an individually optimized dose of 0.125 to 0.75 mg/day for a further 3 months. Patients switched to placebo reached the primary endpoint (a predefined worsening on both the Clinical Global Impressions-Global Improvement scale and the International RLS Study Group Rating Scale) significantly more often than patients who continued to receive pramipexole (85.5% vs. 20.5%; P < 0.0001). They also reached the primary endpoint faster, in 5 versus 42 days to a Kaplan-Meier survival estimate of 0.85 and 7 versus > 84 days to an estimate of 0.5. Over the total 9 months, clinician and patient ratings of symptoms, sleep, and quality of life identified no decline in pramipexole's benefit or tolerability. The great majority of adverse events (AEs) were mild or moderate, and of expected types. Augmentation was considered an AE, but in this population of responders it did not occur. (c) 2006 Movement Disorder Society."],["dc.identifier.doi","10.1002/mds.20983"],["dc.identifier.isi","000240998100016"],["dc.identifier.pmid","16755554"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/29302"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-liss"],["dc.relation.issn","0885-3185"],["dc.title","Controlled withdrawal of pramipexole after 6 months of open-label treatment in patients with restless legs syndrome"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","865"],["dc.bibliographiccitation.issue","8"],["dc.bibliographiccitation.journal","Sleep Medicine"],["dc.bibliographiccitation.lastpage","873"],["dc.bibliographiccitation.volume","9"],["dc.contributor.author","Oertel, Wolfgang Hermann"],["dc.contributor.author","Benes, Heike"],["dc.contributor.author","Garcia-Borreguero, Diego"],["dc.contributor.author","Geisler, Peter"],["dc.contributor.author","Hoegl, Birgit"],["dc.contributor.author","Trenkwalder, Claudia"],["dc.contributor.author","Tacken, Ingrid"],["dc.contributor.author","Schollmayer, Erwin"],["dc.contributor.author","Kohnen, Ralf"],["dc.contributor.author","Stiasny-Kolster, Karin"],["dc.date.accessioned","2018-11-07T11:08:52Z"],["dc.date.available","2018-11-07T11:08:52Z"],["dc.date.issued","2008"],["dc.description.abstract","Background: Long-term efficacy and tolerability data are not yet available for patch formulations of dopamine agonists in restless legs syndrome. Methods: Efficacy and safety of rotigotine (0.5-4 mg/24 h), formulated as a once-daily transdermal system (patch), were investigated in an open extension (SP710) of a preceding 6-week placebo-controlled trial (SP709, 341 randomized patients) in patients with idiopathic restless legs syndrome. For efficacy assessment the international RLS severity scale (IRLS), the RLS-6 scales, the clinical global impressions (CGI) and the QoL-RLS questionnaire were administered. In addition, long-term tolerability and safety were assessed. Results: Of 310 patients who finished the controlled trial, 295 (mean age 58 +/- 10 years, 66% females) with a mean IRLS score of 27.8 +/- 5.9 at baseline of SP709 were included. We report results after one year of this ongoing long-term trial. Two hundred twenty patients (retention rate = 74.6%) completed the 12-month follow-up period. The mean daily dose was 2.8 +/- 1.2 mg/24 h with 4 mg/24 h (40.6%) being the most frequently applied dose; 14.8% were sufficiently treated with 0.5 or 1.0 mg/24 h. The IRLS total score improved by -17.4 +/- 9.9 points between baseline and end of Year 1 (p < 0.001). The other measures of severity, sleep satisfaction and quality of life supported the efficacy of rotigotine (p < 0.001 for pre-post-comparisons of all efficacy variables). The tolerability was described as \"good\" or \"very good\" by 80.3% of all patients. The most common adverse events were application site reactions (40.0%), which led to withdrawal in 13.2%. Further relatively frequent adverse events were nausea (9.5%) and fatigue (6.4%). Two drug-related serious adverse events, nausea and syncope, required hospitalization. Symptoms of augmentation were not reported by the patients. Conclusion: Rotigotine provided a stable, clinically relevant improvement in all efficacy measures throughout one year of maintenance therapy. The transdermal patch was safe and generally well tolerated by the majority of patients. Comparable to any transdermal therapy, application site reactions were the main treatment complication. (c) 2008 Elsevier B.V. All rights reserved."],["dc.description.sponsorship","Schwarz Biosciences GmbH; UCB-Group, Monheim, Germany"],["dc.identifier.doi","10.1016/j.sleep.2008.04.012"],["dc.identifier.isi","000261622500010"],["dc.identifier.pmid","18753003"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/52890"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Science Bv"],["dc.relation.issn","1878-5506"],["dc.relation.issn","1389-9457"],["dc.title","One year open-label safety and efficacy trial with rotigotine transdermal patch in moderate to severe idiopathic restless legs syndrome"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1000"],["dc.bibliographiccitation.issue","8"],["dc.bibliographiccitation.journal","Nature Genetics"],["dc.bibliographiccitation.lastpage","1006"],["dc.bibliographiccitation.volume","39"],["dc.contributor.author","Winkelmann, Juliane"],["dc.contributor.author","Schormair, Barbara"],["dc.contributor.author","Lichtner, Peter"],["dc.contributor.author","Ripke, Stephan"],["dc.contributor.author","Xiong, Lan"],["dc.contributor.author","Jalilzadeh, Shapour"],["dc.contributor.author","Fulda, Stephany"],["dc.contributor.author","Putz, Benno"],["dc.contributor.author","Eckstein, Gertrud"],["dc.contributor.author","Hauk, Stephanie"],["dc.contributor.author","Trenkwalder, Claudia"],["dc.contributor.author","Zimprich, Alexander"],["dc.contributor.author","Stiasny-Kolster, Karin"],["dc.contributor.author","Oertel, Wolfgang"],["dc.contributor.author","Bachmann, Cornelius G."],["dc.contributor.author","Paulus, Walter J."],["dc.contributor.author","Peglau, Ines"],["dc.contributor.author","Eisensehr, Ilonka"],["dc.contributor.author","Montplaisir, Jacques"],["dc.contributor.author","Turecki, Gustavo"],["dc.contributor.author","Rouleau, Guy A."],["dc.contributor.author","Gieger, Christian"],["dc.contributor.author","Illig, Thomas"],["dc.contributor.author","Wichmann, Erich"],["dc.contributor.author","Holsboer, Florian"],["dc.contributor.author","Muller-Myhsok, Bertram"],["dc.contributor.author","Meitinger, Thomas"],["dc.date.accessioned","2018-11-07T11:00:21Z"],["dc.date.available","2018-11-07T11:00:21Z"],["dc.date.issued","2007"],["dc.description.abstract","Restless legs syndrome (RLS) is a frequent neurological disorder characterized by an imperative urge to move the legs during night, unpleasant sensation in the lower limbs, disturbed sleep and increased cardiovascular morbidity. In a genome- wide association study we found highly significant associations between RLS and intronic variants in the homeobox gene MEIS1, the BTBD9 gene encoding a BTB(POZ) domain as well as variants in a third locus containing the genes encoding mitogen- activated protein kinase MAP2K5 and the transcription factor LBXCOR1 on chromosomes 2p, 6p and 15q, respectively. Two independent replications confirmed these association signals. Each genetic variant was associated with a more than 50% increase in risk for RLS, with the combined allelic variants conferring more than half of the risk. MEIS1 has been implicated in limb development, raising the possibility that RLS has components of a developmental disorder."],["dc.identifier.doi","10.1038/ng2099"],["dc.identifier.isi","000248446900018"],["dc.identifier.pmid","17637780"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/50900"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Nature Publishing Group"],["dc.relation.issn","1061-4036"],["dc.title","Genome-wide association study of restless legs syndrome identifies common variants in three genomic regions"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","295"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Sleep Medicine"],["dc.bibliographiccitation.lastpage","305"],["dc.bibliographiccitation.volume","10"],["dc.contributor.author","Happe, Svenja"],["dc.contributor.author","Reese, Jens Peter"],["dc.contributor.author","Stiasny-Kolster, Karin"],["dc.contributor.author","Peglau, Ines"],["dc.contributor.author","Mayer, Geert"],["dc.contributor.author","Klotsche, Jens"],["dc.contributor.author","Giani, Guido"],["dc.contributor.author","Geraedts, Max"],["dc.contributor.author","Trenkwalder, Claudia"],["dc.contributor.author","Dodel, Richard"],["dc.date.accessioned","2018-11-07T08:32:32Z"],["dc.date.available","2018-11-07T08:32:32Z"],["dc.date.issued","2009"],["dc.description.abstract","Background: Restless Legs Syndrome (RLS) has a substantial impact on normal daily activities. Because of the high prevalence it is necessary to evaluate the impact on the health-related quality of life (HRQoL). Objective: To assess health-related quality of life in patients with RLS. Methods: A total of 519 patients (327 female patients; mean age: 64.2 y) were recruited in five different German centers according to the diagnostic criteria of the International RLS Study Group. Patients were either interviewed or completed a mailed questionnaire. The questionnaire consisted of an evaluation of the sociodemographic, clinical and health-related status. HRQoL was evaluated with the EuroQoL (EQ-5D). In addition, the IRLS scale, the MOS Sleep Scale, the Epworth Sleepiness Scale, and the BDI were applied as clinical rating scales. Results: HRQoL is substantially affected by RLS. The mean EQ-5D-VAS was 55.6 and considerably lower compared to the general population. It was found to be as low as in other chronic neurological disorders such as Parkinson's disease and stroke. From different, factors investigated by uni- and multivariate analyses, severity of RLS and depressive symptoms had the most significant impact on HRQoL. Additionally, sleep deficits, the duration of the disease and net household income were identified as predictors for different EQ-5D outcome scores. Conclusions: RLS considerably affects HRQoL. Further comparative studies are necessary to evaluate the effect of disease symptoms on HRQoL and their change due to medication. (C) 2008 Elsevier B.V. All rights reserved."],["dc.identifier.doi","10.1016/j.sleep.2008.01.002"],["dc.identifier.isi","000266225000005"],["dc.identifier.pmid","18359664"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/17362"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Science Bv"],["dc.relation.issn","1878-5506"],["dc.relation.issn","1389-9457"],["dc.title","Assessing health-related quality of life in patients with restless legs syndrome"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","2267"],["dc.bibliographiccitation.issue","16"],["dc.bibliographiccitation.journal","Movement Disorders"],["dc.bibliographiccitation.lastpage","2302"],["dc.bibliographiccitation.volume","23"],["dc.contributor.author","Trenkwalder, Claudia"],["dc.contributor.author","Hening, Wayne A."],["dc.contributor.author","Montagna, Pasquale"],["dc.contributor.author","Oertel, Wolfgang Hermann"],["dc.contributor.author","Allen, Richard P."],["dc.contributor.author","Walters, Arthur S."],["dc.contributor.author","Costa, Joao"],["dc.contributor.author","Stiasny-Kolster, Karin"],["dc.contributor.author","Sampaio, Cristina"],["dc.date.accessioned","2018-11-07T11:07:58Z"],["dc.date.available","2018-11-07T11:07:58Z"],["dc.date.issued","2008"],["dc.description.abstract","Only in the last three decades, the restless legs syndrome (RLS) has been examined in randomized controlled trials. The Movement Disorder Society (MDS) commissioned a task force to perform an evidence-based review of file medical literature on treatment modalities used to manage patients with RLS. The task force performed a search of the published literature using electronic databases. The therapeutic efficacy of each drug was classified as being either efficacious, likely efficacious, investigational, nonefficacious, or lacking sufficient evidence to classify. Implications for clinical practice were generated based on the levels of evidence and particular features of each modality, such as adverse events. All studies were classed according to three levels of evidence. All Level-I trials were included in the efficacy tables if no Level-I trials were available then Level-If trials were included or, in the absence of Level-II trials, Level-III studies or case series were included. Only studies published in print or online before December 31, 2006 were included. All studies published after 1996, which attempted to assess RLS augmentation, were reviewed in a separate section. The following drugs are considered efficacious for the treatment of RLS: levodopa, ropinirole, pramipexole. cabergoline, pergolide, and gabapentin. Drugs considered likely efficacious are rotigotine, bromocriptine, oxycodone, carbamazepine, valproic acid, and clonidine. Drugs that are considered investigational are dihydroergocriptine, lisuride, methadone, tramadol, clonazepam, zolpidem, amantadine, and topiramate. Magnesium, folic acid, and exercise are also considered to be investigational. Sumanirole is nonefficacious. Intravenous iron dextran is likely efficacious for the treatment of RLS secondary to end-stage renal disease and investigational in RLS subjects with normal renal function. The efficacy of oral iron is considered investigational; however, its efficacy appears to depend on the iron status of subjects. Cabergoline and pergolide (and possibly lisuride) require special monitoring due to fibrotic complications including cardiac valvulopathy. Special monitoring is required for several other medications based on clinical concerns: opioids (including, but not limited to, oxycodone, methadone and tramadol), due to possible addiction and respiratory depression, and some anticonvulsants (particularly, carbamazepine and valproic acid), due to systemic toxicities. (c) 2008 Movement Disorder Society"],["dc.identifier.doi","10.1002/mds.22254"],["dc.identifier.isi","000262244600001"],["dc.identifier.pmid","18925578"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/52691"],["dc.language.iso","en"],["dc.notes.status","final"],["dc.notes.submitter","Najko"],["dc.relation.issn","0885-3185"],["dc.title","Treatment of Restless Legs Syndrome: An Evidence-Based Review and Implications for Clinical Practice"],["dc.type","review"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dspace.entity.type","Publication"]]